Indication
PIK3CA-related overgrowth spectrum
PIK3CA-related overgrowth spectrum (PROS) is a heterogeneous group of rare disorders caused by mosaic, postzygotic activating mutations in the *PIK3CA* gene, leading to hyperactivation of the PI3K/AKT/mTOR signaling pathway. Read more about PIK3CA-related overgrowth spectrum
2 drugs 2 manufacturers
Drugs that treat it
Common PIK3CA-related overgrowth spectrum therapies.
VIJOICE (alpelisib)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonPIK3CA-related overgrowth spectrum (PROS) is a heterogeneous group of rare disorders caused by mosaic, postzygotic activating mutations in the *PIK3CA* gene, leading to hyperactivation of the PI3K/AKT/mTOR signaling pathway.
Typically presenting congenitally or in early childhood, the condition is characterized by disproportionate, segmental, or focal overgrowth that can involve adipose tissue, skeletal structures, skin, brain, and the vascular system.
Defining clinical manifestations include asymmetric limb and trunk hypertrophy, complex vascular and lymphatic malformations, epidermal nevi, and central nervous system anomalies such as megalencephaly and cortical dysplasia.
The spectrum unifies several previously distinct clinical entities, including CLOVES syndrome, megalencephaly-capillary malformation (MCAP) syndrome, and isolated macrodactyly or fibroadipose hyperplasia.
- nih.gov
PIK3CA-related overgrowth spectrum (PROS) is a heterogeneous group of rare disorders caused by mosaic, postzygotic activating mutations in the *PIK3CA* gene, leading to hyperactivation of the PI3K/AKT/mTOR signaling pathway Defining clinical manifestations include asymmetric limb and trunk hypertrophy, complex vascular and lymphatic malformations, epidermal nevi, and central nervous system anomalies such as megalencephaly and cortical dysplasia The spectrum unifies several previously distinct cl...
- nih.gov
PIK3CA-related overgrowth spectrum (PROS) is a heterogeneous group of rare disorders caused by mosaic, postzygotic activating mutations in the *PIK3CA* gene, leading to hyperactivation of the PI3K/AKT/mTOR signaling pathway
- nih.gov
Typically presenting congenitally or in early childhood, the condition is characterized by disproportionate, segmental, or focal overgrowth that can involve adipose tissue, skeletal structures, skin, brain, and the vascular system Defining clinical manifestations include asymmetric limb and trunk hypertrophy, complex vascular and lymphatic malformations, epidermal nevi, and central nervous system anomalies such as megalencephaly and cortical dysplasia The spectrum unifies several previously dist...
- childrenshospital.org
Typically presenting congenitally or in early childhood, the condition is characterized by disproportionate, segmental, or focal overgrowth that can involve adipose tissue, skeletal structures, skin, brain, and the vascular system
Personalize your experience
Follow PIK3CA-related overgrowth spectrum and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.